Daily Chart Analysis on

WOCKPHARMA

Daily Chart Analysis on

Wockhardt Pharma (WOCKPHARMA) Wockhardt Pharma (WOCKPHARMA) witnessed a sharp recovery today after five straight sessions of decline, opening at 1426.50, making a low of 1418.20, a high of 1497.30, and finally closing strong at 1488.00. On the daily chart, the stock has been consistently holding the crucial 1400 level while also taking strong support at its 200-day EMA, which indicates that the downside may be limited for now. The recent bounce suggests that the stock has entered a corrective recovery phase, with renewed buying interest visible at lower levels. If this strength continues, the stock has the potential to test 1550–1560 in the near term, and on sustained momentum, it may further extend towards 1600–1610 over the medium term. Overall, as long as the 1400 level remains intact, Wockhardt Pharma appears to be in a favourable position for accumulation on dips, with improving risk-reward prospects. Wockhardt Pharma’s latest strategic shift—exiting the U.S. generics segment and securing a credit rating upgrade—appears to have triggered renewed buying interest, as seen in today’s strong bounce off the 200-day EMA and 1400 support zone. Looking ahead, the Q2 earnings report in early November serves as a key near-term catalyst. A positive outcome could bolster the recovery and potentially extend the stock’s upside momentum.